Novartis Investigative Site
Nuremberg, 90443, Germany
Location status: Recruiting
NCT Number: NCT07508007
Lipoprotein(a) [Lp(a)] is recognised as an independent, non-modifiable genetic risk factor for cardiovascular (CV) disease. Current guidelines from the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) recommend that Lp(a) be measured at least once in every adult's lifetime, however routine Lp(a) testing rates remains infrequent.
The aim of this study is to assess the impact of implementation strategies (IStr) designed to increase the adoption of Lp(a) testing in routine practice, ultimately leading to more individuals being tested in secondary care. This, in turn, is expected to result in the identification and enhanced management of Cardiovascular Disease (CVD) risk patients with elevated Lp(a).
Interested in participating?
Request Info18 year and older
All sexes
Observational
Nuremberg, 90443, Germany
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Each cluster within this study has a set of inclusion criteria. In addition, to be eligible for inclusion in this study, all the following criteria at the cluster-level must be met:
Inclusion criteria
for centers:
Inclusion criteria
for HCP survey participants:
Electronic records are eligible for assessment in this study if they meet all the following criteria:
Exclusion criteria
Exclusion criteria
at center cluster-level includes:
Electronic records will not be assessed for:
Time frame: 12 months pre-IStr, 12 months post IStr
Time frame: 12 months pre-IStr to 6 months post and 12 months pre-IStr to 24 months post
Time frame: 12 months pre-IStr, 12 months post IStr
Change in proportion of patients with at least one Lp(a) test prescribed 12 months post IStr vs 12 months pre-IStr by pre-defined subgroups of interest (including but not limited to high and very high risk , recent MI; recurrent ASCVD; pre-mature ASCVD)
Time frame: 12 months pre-IStr, 12 months post-IStr
Proportion of tested patients with elevated Lp(a) ≥50, ≥70, ≥90, ≥180 mg/dL or ≥125, ≥150, ≥190, ≥396 nmol/dL
Time frame: 6 and 12 months post-IStr
Contact information is provided by the study sponsor or research team.
Novartis Pharmaceuticals
Industry
Lp(a)CCELERATE: Impact of Implementation Strategies on Lp(a) Testing in Secondary Care Settings
Acronym: Lp(a)CCELERATE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.